Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 2Active not recruiting 2Available 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 3Observational 1Expanded_access 1

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 2

Conditions

Burkitt Lymphoma 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Lymphoma 1Leukemia 1

Interventions

pembrolizumab 279Carboplatin 214Cisplatin 145Gemcitabine 144Paclitaxel 142Bevacizumab 115Pemetrexed 112Docetaxel 100Oxaliplatin 78Dexamethasone 77durvalumab 76Fluorouracil 76atezolizumab 75Nivolumab 74Cyclophosphamide 74130-nm albumin-bound paclitaxel 71Fulvestrant 68Cetuximab 63Capecitabine 63Injections 61Leucovorin 60Rituximab 55fludarabine 50Lenalidomide 49venetoclax 43Prednisone 43Irinotecan 42enzalutamide 39Letrozole 39tislelizumab 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × tisagenlecleucel × 90 days × Clear all
NCT03876769 2026-06-02

CASSIOPEIA

Novartis

Phase 2 Active not recruiting
121 enrolled
Lymphoid

Burkitt Lymphoma, Neoplasm, Residual

NCT06785818 2026-05-05

Long-term Follow up Local Registry Study of Kymriah in South Korea

Novartis

Recruiting
500 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT03601442 2026-04-23

Managed Access Programs for CTL019, Tisagenlecleucel

Novartis

Available
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT04094311 2026-04-20

Study of Out of Specification for Tisagenlecleucel

Novartis

Phase 3 Recruiting
200 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05888493 2026-04-17

LEDA

Novartis

Phase 3 Active not recruiting
109 enrolled
Lymphoid

Lymphoma, Follicular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡